目的：观察沙利度胺联合化疗方案治疗晚期非小细胞肺癌（NSCLC）的疗效，及其对血清血管内皮生长因子（VEGF）、碱性成纤维细胞生长因子（bFGF）和肿瘤坏死因子（TNF-α）水平的影响。方法选取晚期NSCLC患者87例，随机分为观察组45例，对照组42例，对照组给予NP方案化疗，观察组在此基础上联合沙利度胺治疗，观察2组患者的临床疗效及血清VEGF、bFGF及TNF-α指标水平的变化。结果观察组临床受益率（CBR）显著高于对照组（P＜0．01）。治疗后2组患者血清VEGF水平均显著下降（P＜0．05），观察组血清bFGF水平显著下降（P＜0．05），对照组血清bFGF水平与治疗前无显著差异（P＞0．05）。2组患者治疗后血清TNF-α水平显著低于治疗前（P＜0．05或P＜0．01），且观察组显著低于对照组（P＜0．05）。结论沙利度胺联合化疗治疗晚期NSCLC具有一定的优势，能降低血清VEGF、bFGF及TNF-α指标水平。%Objective To observe the efficacy of thalidomide combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)and its influence on vascular endothe-lial growth factor (VEGF),basic fibroblast growth factor (bFGF)and tumor necrosis factor-α(TNF-α).Methods A total of 87 patients with advanced NSCLC were enrolled and randomly divided into observational group (45 cases)and control group (42 cases).Patients in control group received NP regimen while patients in observational group received thalidomide +NP regimen.The clinical effica-cy and the changes of the levels of VEGF,bFGF and TNF-αwere observed.Results Clinical benefit rate (CBR)of observational group was significantly higher than control group (P<0.01).Compared with treatment before,the levels of VEGF in 2 groups decreased significantly (P<0.05)and the lev-els of bFGF in observational group reduced obviously (P<0.05 )but there was no significant differ-ence between treatment before and after treatment (P>0.05).The level of TNF-αafter treatment in 2 groups was obviously lower than treatment before (P<0.05,or P<0.01 )and observational group was significantly lower than control group (P <0.05 ).Conclusion Thalidomide combined with chemotherapy can reduce the level of VEGF,bFGF and TNF-αin the treatment of advanced NSCLC.
展开▼
